Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695290 · ClinicalTrials.gov registry record · Phase 4
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02695290: Clinical Trial Phase 4 study, sponsored by Boehringer Ingelheim.
NCT02695290 is a Phase 4 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02695290, a Phase 4 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
Primary Outcome
Percentage of patients with occurrence of Adverse Events (AEs) leading to dose reduction of afatinib.
Interventions
- DRUG Afatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-03-17 |
| Est. Completion | 2016-08-26 |
| Phase | Phase 4 |
Why NCT02695290 stopped before completion
NCT02695290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Afatinib is the first listed.
NCT02695290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02695290 about?
NCT02695290 is a clinical study titled "Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)". There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
What is the current status of trial NCT02695290?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2016-03-17. Estimated completion is 2016-08-26.
What interventions are being tested in trial NCT02695290?
The interventions under investigation include: Afatinib (DRUG).
Who is sponsoring clinical trial NCT02695290?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02695290's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI